As Quality of life (QoL) is an important outcome measure in clinical trials and is increasingly being used as an end point, especially in studies involving patients with malignant diseases, we therefore aim to evaluate patients’ expectations about the impact of ¹⁷⁷LutetiumPSMA  on their health related quality of life (HRQol) and their actual quality of life. We will also be able to assess the quality of life in elderly patients, and those with multiple comorbidities (ECOG performance status at baseline between 0 to 2 ),when being treated with¹⁷⁷LutetiumPSMA , as there are few studies evaluating the health related quality of life (HRQol) in these two subgroup